← All trials
NCT03901690
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 27, 2019
- Primary completion
- Jun 22, 2019
- Completion date
- Jul 22, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo FabbriLead sponsor
- Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo FabbriStudy chair
- Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo FabbriReponsible party - principal investigator
- CaloxCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.